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–15 min) and after (0–15 and 60–75 min) pertuzumab/
placebo infusions (Cycles 1 and 3), and at 72 h post-infu-
sion (Cycle 1). Fridericia’s correction was applied to QT 
measurements (QTcF) and change from baseline (ΔQTcF) 
calculated. Statistical analyses were performed on base-
line-adjusted, placebo-corrected QTcF values (ΔΔQTcF). 
Linear mixed-effects modeling evaluated potential expo-
sure–response relationships between ΔQTcF and observed 
pertuzumab concentrations.
Results Thirty-seven female patients participated in the 
substudy. QTcF values in both groups were within the nor-
mal range and below critical thresholds of clinical concern. 
No pertuzumab-treated patient showed abnormal electro-
cardiogram morphology. In Cycle 1, mean ΔΔQTcF (90 % 
CI) values at 0–15 min, 60–75 min, and 72 h post-infu-
sion were −6.96 (−13.69, −0.23), −6.35 (−13.57, 0.88), 
and −4.08 (−12.64, 4.48), all of which were <5 ms, with 
upper CI limits <10 ms. One Cycle 3 post-infusion mean 
ΔΔQTcF value exceeded 5 ms. Other electrocardiogram 
parameters were within normal ranges. Concentration–
QTc modeling showed no apparent relationship between 
ΔQTcF and pertuzumab concentrations.
Conclusions Cardiac monitoring and concentration–
QTc modeling demonstrated that pertuzumab, combined 
with trastuzumab and docetaxel, had no clinically relevant 
effects on QTcF and other electrocardiogram parameters.
Keywords Cardiac repolarization · HER2-positive 
metastatic breast cancer · Pertuzumab · QT
Introduction
Although improved early detection and advances in sys-
temic therapy for early stage disease have resulted in a 
Abstract 
Purpose The phase III trial of pertuzumab plus trastu-
zumab plus docetaxel versus placebo plus trastuzumab 
plus docetaxel for first-line treatment of HER2-positive 
metastatic breast cancer included a substudy to determine 
whether pertuzumab affected the corrected QT (QTc) inter-
val or other electrocardiogram parameters.
Methods Triplicate 12-lead electrocardiogram measure-
ments and serum samples were collected before (–30 and 
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decline in breast cancer mortality in recent years [1, 2], 
metastatic breast cancer (MBC) remains essentially incur-
able. Human epidermal growth factor receptor 2 (HER2), a 
cell-surface receptor involved in regulation of cell growth, 
survival, and differentiation [3], has emerged as one of the 
most important targets in breast cancer treatment. Around 
15–20 % of breast cancers exhibit amplification and/or 
overexpression of HER2 (“HER2-positivity”) [4–6], which 
is associated with increased tumor aggressiveness, higher 
rates of recurrence, and increased mortality [6–11]. There 
is a significant need for new anti-HER2 agents with novel 
mechanisms of action and non-overlapping toxicity, which 
can be combined with established treatments for breast 
cancer.
Pertuzumab (rhuMAb 2C4) is a humanized monoclo-
nal anti-HER2 antibody that prevents heterodimerization 
of HER2 with other members of the HER family (HER1, 
HER3, and HER4), thus inhibiting ligand-activated down-
stream signaling [12]. The combination of pertuzumab, 
with trastuzumab, another HER2-targeted humanized mon-
oclonal antibody, and docetaxel is indicated for first-line 
treatment of HER2-positive MBC [13]. Although both anti-
bodies target HER2, pertuzumab and trastuzumab bind to 
distinct epitopes in the extracellular domain (ECD) of the 
receptor and have complementary mechanisms of action 
[14]. While pertuzumab prevents the ligand-activated for-
mation of HER2 heterodimers, trastuzumab prevents the 
shedding of the HER2 ECD (thereby blocking formation 
of constitutively active truncated receptors) and disrupts 
ligand-independent HER2–HER3–phosphatidylinositol 3- 
kinase (PI3 K) complex formation [14–16].
The efficacy and safety of pertuzumab, in combination 
with trastuzumab plus docetaxel for the first-line treatment 
of HER2-positive MBC, were demonstrated in the interna-
tional, randomized, double-blind, placebo-controlled phase 
III CLEOPATRA trial, which involved approximately 800 
patients [13, 17]. In this study, pertuzumab was admin-
istered every 3 weeks by IV infusion at an initial dose of 
840 mg in Cycle 1, followed by 420 mg in subsequent 
cycles. The results of the primary endpoint demonstrated a 
significant increase in progression-free survival (PFS) with 
pertuzumab plus trastuzumab plus docetaxel, as compared 
with placebo plus trastuzumab plus docetaxel, with a 6.1-
month increase in median PFS with pertuzumab-containing 
therapy [13, 17]. Overall survival was also significantly 
improved in the pertuzumab arm compared with the control 
arm [18].
Novel pharmaceutical agents should undergo rigorous 
evaluation for their potential to delay cardiac repolarization 
[19]. Assessed as prolongation of the QT interval on the 
electrocardiogram (ECG), a delay in cardiac repolarization 
creates an electrophysiological environment that favours 
the development of ventricular arrhythmias, most notably 
torsade de pointes (TdP), which may lead to sudden death. 
The International Conference on Harmonisation (ICH) 
E14 document recommends that all systemically available 
drugs, other than those intended for the control of arrhyth-
mias, should undergo careful clinical testing in a thorough 
QT/corrected QT (QTc) interval study [19, 20]. However, 
challenges exist in implementing a thorough QT study for 
oncology drugs; for example, potential toxicities preclude 
administration of therapeutic doses to healthy volunteers 
or supratherapeutic doses to patients with cancer, and pro-
longing periods without active treatment is unethical [21]. 
Moreover, monoclonal antibodies such as pertuzumab are 
expected to have a lower potential to affect the QT inter-
val due to their large molecular size, which precludes direct 
access to the hERG channel drug-binding site, and high tar-
get specificity compared with small-molecule agents [22]. 
Of note, trastuzumab, another anti-HER2 antibody, was 
found to have no significant effect on the QT interval or 
other ECG parameters when administered to patients with 
MBC [23], whereas docetaxel has been associated with a 
proarrhythmogenic effect [24].
In cases where a thorough QT study in healthy volun-
teers is considered impractical or unethical, dedicated 
ECG monitoring for evaluation of possible effects on the 
QTc interval, PR interval, and heart rate (HR), supported 
by concentration–QTc modeling, can be considered as an 
alternative approach to investigate potential drug-induced 
cardiac effects [19, 20]. Therefore, a substudy of the phase 
III CLEOPATRA trial was conducted to determine whether 
pertuzumab affected cardiac repolarization when com-
bined with trastuzumab and docetaxel for the first-line 
treatment of MBC. ECG and pharmacokinetic (PK) data 
were collected during Cycles 1 and 3 in order to charac-
terize the QTc interval and other ECG parameters during 
study treatment, and to assess potential concentration–QTc 
relationships.
Methods
Substudy design and ethics
CLEOPATRA was a phase III trial performed to assess the 
efficacy and safety of pertuzumab (PERJETA®, F. Hoff-
mann-La Roche, Basel, Switzerland; Genentech Inc., South 
San Francisco, CA) plus trastuzumab plus docetaxel, as 
compared with placebo plus trastuzumab plus docetaxel, 
as first-line treatment for patients with HER2-positive 
MBC [13, 17]. The trial was conducted in full accord-
ance with the guidelines for Good Clinical Practice and 
the Declaration of Helsinki. A subset of clinical sites from 
the CLEOPATRA study participated in the PK/QTc sub-
study with the goal of assessing the effect of pertuzumab 
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on cardiac repolarization. The protocol of the substudy, the 
Informed Consent Form, and relevant supporting informa-
tion were submitted to an Institutional Review Board (IRB) 
or Ethics Committee (EC) for review and approval before 
initiation of the substudy. The Principal Investigator was 
responsible for providing written summaries of the status 
of the study to the IRB/EC. Written informed consent was 
obtained from each individual participating in this study, 
after adequate explanation of the aims, methods, antici-
pated benefits, objectives, and potential hazards.
Patients and treatment
Patients enrolled in the substudy received the same treat-
ments as specified in the main CLEOPATRA study. In 
the control arm, patients received a pertuzumab placebo 
infusion starting on Day 1 of Cycle 1, plus a trastuzumab 
8 mg/kg IV loading dose (followed by 6 mg/kg IV every 
3 weeks until disease progression or unacceptable toxicity) 
and docetaxel 75 mg/m2 IV (every 3 weeks for at least six 
cycles, or until disease progression or unacceptable toxic-
ity) starting on Day 2 of Cycle 1. Treatment in the experi-
mental arm included a pertuzumab 840 mg IV loading dose 
starting on Day 1 of Cycle 1 (followed by 420 mg IV every 
3 weeks until progressive disease or unacceptable toxicity), 
plus trastuzumab and docetaxel administered as in the con-
trol arm. Study treatment cycles were 3 weeks (21 days) in 
length.
The first dose of pertuzumab/placebo (Cycle 1, Day 1) 
was planned within 3 days of randomization. The first dose 
of trastuzumab was administered 24 h later (Cycle 1, Day 
2), followed by the first dose of docetaxel on the same day. 
If the initial infusions of all three agents were well toler-
ated, as determined by the investigator, subsequent doses of 
trastuzumab and docetaxel could also be administered on 
Day 1 of each cycle. At the discretion of the treating physi-
cian, the docetaxel dose could be increased to 100 mg/m2 
according to tolerability. The following treatment sequence 
was used when all drugs were given on the same day: per-
tuzumab/placebo, trastuzumab, and docetaxel.
ECG and PK data collection
Twelve-lead ECG measurements were obtained in triplicate 
from resting, supine patients before (−30 and −15 min) 
and after (0–15 and 60–75 min) pertuzumab/placebo infu-
sion on Day 1 of Cycles 1 and 3, and on Day 3 of Cycle 
1 (approximately 72 h after the pertuzumab/placebo infu-
sion). Blood draws and other procedures were avoided 
immediately before ECG data collection, and timing of 
meals was standardized as much as possible between 
patients. ELI 250 (Mortara Instrument, Inc., Milwaukee, 
WI) machines were supplied to substudy sites and used 
with standard lead placement. The same machine was used 
for all ECGs obtained from each individual patient. Raw 
ECG data were sent to a central core cardiology laboratory, 
where ECG readers, who were blinded to treatment and 
ECG time point, produced a single dataset for automated 
analysis. ECG measurements included QRS duration, PR 
interval, HR, QT intervals, RR intervals, U waves, T waves, 
and instances of abnormal ECG morphology.
Blood samples were drawn immediately after the cor-
responding ECG assessments for PK analyses. Serum per-
tuzumab concentrations were measured with a validated 
bridging enzyme-linked immunosorbent assay (ELISA), 
which used a monoclonal anti-idiotype antibody to cap-
ture pertuzumab from serum samples. The minimum 
quantifiable concentration of pertuzumab in serum was 
150 ng/ml [25].
Statistical analyses
Demographic data and baseline characteristics were sum-
marized with descriptive statistics for the two treatment 
groups. In order to reduce the dependence of QT on HR, 
Fridericia’s correction was applied (QTcF = QT/RR0.33) 
[19]. Bazett’s formula was additionally used to correct for 
HR, but was found to provide poorer correction compared 
with Fridericia’s method (data not shown). All presented 
analyses are therefore based on QTcF.
Individual QTcF measurements were summarized with 
descriptive statistics by cycle, treatment, and time point. 
Incidences of abnormal ECG results of clinical and regu-
latory interest [19] at screening and post-screening were 
tabulated and summarized using graphical displays. These 
included: new incidences of QTcF values >450, >480, or 
>500 ms; change from baseline in QTcF (ΔQTcF) >30 
or >60 ms; change from baseline HR (ΔHR) ≥25 %, 
resulting in final HR <50 or >120 bpm; change from base-
line PR (ΔPR) ≥25 %, resulting in final PR >200 ms; 
change from baseline QRS (ΔQRS) ≥25 %, resulting in 
final QRS >110 ms; and new incidences of abnormal U 
waves, T waves, or ECG morphology.
Baseline ECG was defined as the average of pre-dose 
observations at Cycle 1, Day 1 (i.e., 15 min and 30 min 
prior to infusion), and this Cycle 1 baseline was used for all 
analyses in the substudy (including those in Cycle 3). Base-
line-adjusted, placebo-corrected QTcF (ΔΔQTcF) values 
were derived using the following formula:
Descriptive statistics of ΔΔQTcF were presented by treat-
ment, cycle, and time point. Point estimates of ΔΔQTcF 
and two-sided 90 % confidence intervals (CIs) were derived 
by inverting the results of a t test. The variance of the 
∆∆QTcF = (mean of ∆QTcF for pertuzumab group)
− (mean of ∆QTcF for placebo group) .
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difference of means was calculated using either a pooled 
or Satterthwaite estimate of the variance depending on the 
p value of the F test for equality of variances (α = 0.10). 
Descriptive and inferential statistics were calculated using 
SAS Version 9.2 (SAS Institute Inc., Cary, NC).
The concentration–QTcF relationship was explored 
using linear mixed-effects analyses [26]. The dataset con-
sisted of observed drug concentrations and ΔQTcF values 
collected on Day 1 of Cycles 1 and 3. For patients who 
received placebo group treatment, concentrations were set 
to zero. Data points were excluded if either the ECG or 
concentration data were missing. The concentration–QTcF 
relationship was assessed according to the following equa-
tion [26]:
where Y is the response variable (i.e., ΔQTcF), the inter-
cept α represents the mean response, and the slope β repre-
sents the change in mean for a unit change in pertuzumab 
serum concentration. The statistical significance of the 
slope parameter (β) corresponds to the following hypoth-
esis testing:
Using a statistical criterion of p < 0.05, this corresponds to 
a change in the objective function, defined as (−2) * log-
likelihood, of 3.83 units. Interindividual variability, as a 
random effect (an additive term), was estimated for inter-
cept (α) and, if possible, slope (β), as well as their corre-
lation. Random effects were assumed to be normally dis-
tributed with mean zero and variance ω2. The matrix Ω 
becomes diagonal when the correlation is zero. The addi-
tive measurement error ε was assumed to be normally dis-
tributed with mean zero and unknown constant variance σ2 
[26]. Graphical presentation and linear mixed-effects mod-
eling were performed using TIBCO Spotfire S-Plus® soft-
ware, Version 8.1 (TIBCO Spotfire Inc., Somerville, MA).
Results
Patient demographics
Descriptive statistics of demographic data and other base-
line characteristics in patients from the substudy were simi-
lar between the two arms and were consistent with those of 
the overall CLEOPATRA study population (Supplementary 
Table 1) [13]. In total, 37 female patients were enrolled in 
the substudy, of whom 20 received pertuzumab plus trastu-
zumab plus docetaxel and 17 received placebo plus trastu-
zumab plus docetaxel. The mean age was 53.1 years, and 
a total of 33 patients (89.2 %) were <65 years of age. Sub-
study participants had a mean weight of 70.9 kg.





H0 : β = 0 and H1 : β �= 0.
QTcF
Descriptive statistics of QTcF data by cycle, treatment, and 
time point are presented in Table 1. Of note, mean baseline 
QTcF, defined as the mean of the raw QTcF values at both 
pre-infusion time points in Cycle 1, was 410.7 ms in the 
pertuzumab group and 420.0 ms in the placebo group. In 
Cycle 1, mean and median QTcF pre-infusion time point 
values were consistent with values at the 0–15 min and 60–
75 min post-infusion time points for both treatment groups. 
Similarly, pre-infusion mean and median QTcF values in 
Cycle 3 were consistent with those observed post-infusion 
for the pertuzumab and placebo groups. Absolute QTcF 
values were within the normal range for women and below 
critical thresholds associated with the development of TdP/
sudden death [27]. In the placebo group, mean QTcF on 
Day 3 of Cycle 1 (420.5 ms) was similar to values observed 
on Day 1 at 0–15 min and 60–75 min post-infusion (420.5 
and 419.4 ms, respectively); suggesting that docetaxel 
treatment on Day 2 had no effect on QTcF on Day 3.
Abnormal ECG results of clinical and regulatory inter-
est were analyzed for both treatment groups (Fig. 1). Over-
all, no patient in the pertuzumab arm showed QTcF values 
of >450 ms, whereas two patients in the placebo arm had 
QTcF values of >450 ms; however, there were no inci-
dences of QTcF values of >480 ms or >500 ms in either 
treatment group. No changes from baseline in QTcF of 
>30 ms occurred in the pertuzumab group, whereas such 
changes were recorded for four patients in the placebo 
group. Changes from baseline in QTcF did not exceed 
60 ms for any patient enrolled in the substudy.
ΔQTcF and ΔΔQTcF
To further assess the potential effect of study treatment 
in the pertuzumab arm relative to that in the placebo arm, 
summary statistics of ΔQTcF and ΔΔQTcF in Cycles 1 
and 3 were prepared (Table 2; Supplementary Fig. 1). In 
Cycle 1, upper ranges of ΔQTcF for the pertuzumab group 
were <30 ms for all three post-infusion time points. Point 
estimates of ΔΔQTcF measured 0–15 min, 60–75 min, 
and 72 h post-infusion were −6.96, −6.35, and −4.08 ms, 
respectively, all of which were <5 ms, with upper limits of 
the corresponding 90 % CIs of <10 ms.
In Cycle 3, mean ΔQTcF values for both post-infusion 
time points in the pertuzumab and placebo groups were 
<5 ms. Variability of ΔQTcF data in the placebo group 
was markedly higher than that observed in the pertuzumab 
group. Mean values of ΔΔQTcF for the 0–15 min and 
60–75 min post-infusion time points were 8.41 ms (90 % 
CI −2.58, 19.39) and −0.04 ms (90 % CI −11.12, 11.04), 
respectively. Although the upper limits of the 90 % CIs for 
both time points were >10 ms, the 90 % CIs also included 
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0 ms. Importantly, the Cycle 3 post-infusion QTcF values 
in the placebo arm were lower than baseline (i.e., pre-infu-
sion Cycle 1), leading to lower point estimates of ΔQTcF 
in the placebo arm in Cycle 3. The resulting overcorrection 
would then account for the inflation of ΔΔQTcF estimates, 
rather than a true drug effect on QTcF.
Concentration–QTcF modeling
The dataset for the exposure–response analysis contained 
33 patients with baseline QTc data and at least one subse-
quent QTc observation with a corresponding PK sample. In 
the pertuzumab group, mean (± standard deviation) serum 
pertuzumab concentrations were 272 ± 49 μg/ml at 60–
75 min post-infusion in Cycle 1, 65 ± 49 μg/ml at 15 min 
pre-infusion in Cycle 3, and 186 ± 33 μg/ml at 60–75 min 
post-infusion in Cycle 3. Pertuzumab arm of all patients 
had measureable serum pertuzumab concentrations prior to 
the Cycle 3 infusion (range 19–245 μg/ml).
An exploratory analysis was performed to assess the 
shape of the concentration–QTcF relationship. As shown 
in Fig. 2, there was no apparent relationship between indi-
vidual serum pertuzumab concentrations and ΔQTcF in 
Cycles 1 and 3. Because the exploratory data analysis iden-
tified intercycle variability in intercept (α) between Cycles 
1 and 3, a cycle-specific intercept was tested for statisti-
cal significance. Results of the linear mixed-effects model 
building are presented in Table 3. The slope estimate of 
−0.0093 with standard error (SE) of 0.0167 was not sta-
tistically significant (p > 0.05), indicating no apparent 
Table 1  QTcF in Cycles 1 and 3, by treatment arm
QTcF QT interval, corrected for heart rate using Fridericia’s correction
Time point QTcF (ms)
Placebo + trastuzumab + docetaxel Pertuzumab + trastuzumab + docetaxel
n Mean ± SD Median (range) n Mean ± SD Median (range)
Cycle 1 30 min prior to infusion 15 420.5 ± 21.77 425.7 (375.0, 466.5) 18 411.3 ± 15.10 417.7 (378.3, 432.7)
15 min prior to infusion 15 419.4 ± 20.40 424.3 (367.7, 444.0) 18 410.1 ± 17.29 416.7 (374.7, 433.0)
0–15 min post-infusion 15 426.9 ± 19.19 425.3 (391.7, 451.0) 20 415.9 ± 18.35 419.5 (367.3, 444.3)
60–75 min post-infusion 17 426.6 ± 18.13 423.3 (380.0, 451.0) 17 410.5 ± 18.98 414.0 (374.7, 431.3)
72 h post-infusion 17 420.5 ± 11.06 418.7 (394.3, 439.0) 17 409 ± 13.80 409.7 (386.0, 431.3)
Cycle 3 30 min prior to infusion 17 411.9 ± 19.01 413.7 (374.7, 440.7) 19 407.6 ± 17.10 408.0 (362.3, 431.0)
15 min prior to infusion 17 410.1 ± 17.47 411.0 (378.3, 452.0) 19 405.8 ± 17.53 408.0 (354.7, 430.0)
0–15 min post-infusion 17 415.2 ± 21.77 416.7 (379.0, 451.7) 19 413.2 ± 16.23 416.7 (374.3, 438.3)
60–75 min post-infusion 17 416.1 ± 21.49 415.3 (375.0, 453.3) 19 407.9 ± 18.25 410.7 (369.7, 436.7)
Fig. 1  Summary of incidence 
of ECG abnormalities by cycle 
and time point. Triangles indi-
cate that at least one pertu-
zumab-treated patient (gray 
triangles) or placebo-treated 
patients (black triangles) had a 
positive test result at that time 
point. ECG electrocardiogram, 
QTcF QT interval, corrected 
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relationship between ΔQTcF and pertuzumab serum con-
centrations. A statistically significant difference in intercept 
by cycle was observed, with a mean (±SE) difference of 
−9.5 ± 2.8 ms between Cycles 3 and 1, as a result of inter-
cycle variability in baseline QTcF. Residual intra-patient 
variability (the standard deviation of ΔQTcF within a 
patient) was 12.3 ms, expressed as the square root of the 
estimated variance. Residuals of ΔQTcF derived from 
the final model were homogeneously distributed around 
0, suggesting no bias in predicting high and low values of 
ΔQTcF (Fig. 3).
Discussion
Prolongation of the QTc interval, resulting in increased sus-
ceptibility to cardiac arrhythmia, is a recognized property 
of many pharmaceutical agents used across a wide range 
of therapeutic settings. Novel, systemically available agents 
should ideally undergo a thorough QT evaluation in healthy 
volunteers, but where such a study is deemed impractical 
or unethical, dedicated ECG monitoring supported by con-
centration–QTc modeling is recommended to investigate 
potential drug-induced cardiac effects [19, 20]. Since per-
tuzumab is an anti-HER2 IgG1 monoclonal antibody with 
a long half-life of approximately 18 days [28], a multiple-
dose study in healthy volunteers or a crossover study in 
HER2-positive MBC involving a washout period and pla-
cebo treatment was not deemed ethical. Therefore, a paral-
lel-design study was performed in the target patient popula-
tion treated with the intended marketed dose and schedule 
of pertuzumab (i.e., 840 mg IV loading dose followed by 
420 mg IV every 3 weeks). This substudy was conducted in 

















































































































































































































































































































































































































































































































Fig. 2  Plot of serum pertuzumab concentrations versus ΔQTcF in 
Cycles 1 and 3. The black line is a LOESS smooth curve with 70 % 
span. QTcF QT interval, corrected for heart rate using Fridericia’s 
correction
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evaluate the effect of pertuzumab on cardiac repolarization 
when administered in combination with trastuzumab and 
docetaxel in patients with HER2-positive MBC.
In Cycle 1, the upper range of ΔQTcF for the pertu-
zumab group was <30 ms at all post-infusion time points, 
and point estimates of ΔΔQTcF were all <5 ms, with cor-
responding upper limits of the 90 % CIs <10 ms. These 
findings indicate that pertuzumab did not prolong QTcF 
in this first cycle, during which pertuzumab serum con-
centrations were at their highest owing to administration 
of the loading dose. In Cycle 3, mean ΔQTcF values for 
both post-infusion time points in the pertuzumab and pla-
cebo groups were <5 ms. Mean ΔΔQTcF for the 0–15 min 
and 60–75 min post-infusion time points in Cycle 3 was 
8.41 and −0.04 ms, respectively, and 90 % CIs for both 
values included 0 and 10 ms. Importantly, mean baseline 
QTcF was 9.3 ms lower in the pertuzumab arm compared 
with the placebo arm (410.7 vs. 420.0 ms, respectively), 
and the Cycle 3 post-infusion QTcF values in the pla-
cebo arm were lower than baseline leading to lower point 
estimates of ΔQTcF in the placebo arm in Cycle 3. As a 
result, ΔΔQTcF values may have been inflated due to the 
overcorrection associated with the low ΔQTcF in the pla-
cebo group.
In assessing the findings of this substudy, it is important 
to consider two additional factors: the normal QTc and the 
absolute value of clinical concern. The E14 guidance docu-
ment notes that QTc prolongation of >500 ms or QTc inter-
val increases from baseline of >60 ms are commonly used 
thresholds at which drug discontinuation may be consid-
ered in a given individual [19, 20, 29]. In the present sub-
study, no pertuzumab-treated patients had absolute QTcF 
values of >450 ms or ΔQTcF of >30 ms, further support-
ing a lack of clinically meaningful effect of pertuzumab 
on the QT interval when combined with trastuzumab and 
docetaxel.
Additional evidence for the absence of a QT effect was 
provided by the exposure–response model, which showed 
no apparent relationship between serum pertuzumab con-
centrations and ΔQTcF. There are limitations to using 
a concentration–QTc modeling approach to investigate 
potential cardiac effects of monoclonal antibodies target-
ing cell-surface proteins, since such agents often exhibit 
nonlinear pharmacokinetics and serum exposures may 
not directly correlate with pharmacodynamic effects [22]. 
However, pertuzumab shows linear pharmacokinetics at 
clinical doses [28], and point estimates of ΔQTcF were 
generally unremarkable irrespective of the time point 
analyzed.
The absence of clinically relevant effect of pertuzumab 
on the QTc interval is consistent with its large molecular 
size, which precludes direct access to the hERG channel 
drug-binding site. Similar results have been reported from a 
small study of trastuzumab in 20 patients with HER2-posi-
tive MBC, in which no significant changes in ECG parame-
ters, including QT and RR intervals or QT dispersion, were 
noted following drug infusion [23]. These clinical find-
ings are also consistent with results from two multi-dose 
toxicology studies in cynomolgus monkeys. Following 
administration of pertuzumab at doses of up to 150 mg/kg 
for more than 26 weeks, there was no evidence of cardiac 
injury in either of these nonclinical studies, as evidenced 
by histopathology, lack of elevations in serum cardiac 
Table 3  Parameter estimates and variability derived with final concentration QTcF linear mixed-effects model
CI confidence interval, CV coefficient of variation, QTcF QT interval, corrected for heart rate using Fridericia’s correction, ΔQTcF baseline-
adjusted QTcF, ΔΔQTcF baseline-adjusted, placebo-corrected QTcF, SE standard error
Parameter Estimate SE CV % 95 % CI (SE-derived)
Intercept for Cycle 1 (ms) 3.4 2.8 82 % −2.1, 8.9
Between-subject variability (ms) 9.4
Difference in intercept (Cycle 3 vs. Cycle 1) −9.5 2.8 29 % −15.0, −4.0
Slope (ms/μg/ml) NS – –





























Fig. 3  Plot of residuals of predicted ΔQTcF versus observed serum 
pertuzumab concentrations of pertuzumab. The black line is a LOESS 
smooth curve with 70 % span. QTcF QT interval, corrected for heart 
rate using Fridericia’s correction
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markers, and normal ECGs, blood pressures and heart rates 
(unpublished data on file, Genentech, Inc.). Although taxa-
nes have been associated with a certain potential for cardio-
toxicity [24], the present substudy found no evidence that 
docetaxel treatment, when initiated on Day 2 of Cycle 1, 
affected QTcF.
It is important to acknowledge the limitations of the 
present substudy compared with a thorough QT study. Of 
note, the omission of a positive control (e.g., moxifloxacin) 
meant that it was not possible to confirm the sensitivity of 
the assay. However, the design of the substudy reflects the 
practical and ethical constraints of the treatment setting 
and is consistent with the recommendations of the Cardiac 
Safety Research Consortium on QT assessment for thera-
peutic proteins, which are expected to have low potential to 
affect cardiac electrical activity [22].
In conclusion, statistical analyses of ΔQTcF and 
ΔΔQTcF and results of concentration–QTc modeling in 
the current substudy suggest that pertuzumab has no clini-
cally relevant effect on QTcF and other ECG parameters in 
patients with HER2-positive MBC. Absolute QTcF values 
were within the normal range for women and below thresh-
old values associated with signals of clinical relevance in 
the development of TdP/sudden death [27].
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